Loading...
XSHG600594
Market cap407mUSD
Dec 27, Last price  
3.78CNY
1D
2.16%
1Q
5.88%
Jan 2017
-77.30%
Name

Guizhou Yibai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600594 chart
P/E
28.77
P/S
1.07
EPS
0.13
Div Yield, %
1.38%
Shrs. gr., 5y
—
Rev. gr., 5y
-6.48%
Revenues
2.78b
+1.56%
631,907,374739,373,109717,180,0471,006,318,9651,153,937,5491,307,399,6021,467,465,0051,903,335,2522,252,575,4862,784,900,0203,157,075,0763,302,519,1833,686,822,7763,807,661,7583,882,863,1793,361,025,7453,413,192,8863,346,704,6052,735,262,8382,777,902,360
Net income
103m
56,343,63969,417,695092,742,58298,131,064121,807,211195,558,577265,483,488333,268,220429,153,586461,165,002171,142,434373,033,839387,529,7930141,895,198219,892,637243,772,1060103,399,049
CFO
378m
+9.36%
017,383,19295,772,39511,943,485189,259,328103,884,268115,660,561277,826,783288,014,258577,241,280541,581,197573,678,658380,616,139681,776,508214,297,431362,713,743366,657,366934,211,133345,299,144377,609,812
Dividend
Jun 07, 20240.066 CNY/sh

Profile

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.
URL
https://www.gzcci.com/
IPO date
Mar 23, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,777,902
1.56%
2,735,263
-18.27%
3,346,705
-1.95%
Cost of revenue
2,233,952
2,274,307
2,644,762
Unusual Expense (Income)
NOPBT
543,950
460,956
701,943
NOPBT Margin
19.58%
16.85%
20.97%
Operating Taxes
40,964
46,261
79,574
Tax Rate
7.53%
10.04%
11.34%
NOPAT
502,987
414,695
622,369
Net income
103,399
 
243,772
10.86%
Dividends
(41,177)
(102,951)
Dividend yield
0.91%
1.60%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
446,045
705,466
574,608
Long-term debt
447,945
401,631
340,756
Deferred revenue
106,314
100,184
67,599
Other long-term liabilities
194,385
649
1
Net debt
157,859
477,279
324,261
Cash flow
Cash from operating activities
377,610
345,299
934,211
CAPEX
(130,382)
Cash from investing activities
(115,594)
Cash from financing activities
(151,690)
168,869
FCF
1,410,989
151,974
718,617
Balance
Cash
699,469
592,355
379,628
Long term investments
36,662
37,462
211,475
Excess cash
597,236
493,055
423,768
Stockholders' equity
2,049,203
2,456,089
2,796,307
Invested Capital
3,479,035
3,810,666
4,030,345
ROIC
13.80%
10.58%
15.45%
ROCE
13.22%
10.64%
15.65%
EV
Common stock shares outstanding
791,927
791,927
791,927
Price
5.69
2.89%
5.53
-31.98%
8.13
55.75%
Market cap
4,506,067
2.89%
4,379,359
-31.98%
6,438,370
55.75%
EV
4,797,736
5,002,337
6,821,883
EBITDA
745,059
642,433
851,885
EV/EBITDA
6.44
7.79
8.01
Interest
22,675
37,476
35,130
Interest/NOPBT
4.17%
8.13%
5.00%